ARA-290 (Cibinetide) – 10MG Research-Use-Only Peptide

ARA-290, also referred to in the literature as cibinetide, is a short synthetic peptide derived from the helix-B surface region of erythropoietin (EPO). Unlike native EPO, ARA-290 does not bind the classical erythropoietin receptor homodimer and is not associated with erythropoietic (red blood cell-stimulating) activity. This product is provided in a 10 mg vial formulation intended solely for controlled research environments.

Research Context

ARA-290 was developed to isolate the tissue-protective properties of erythropoietin from its hematopoietic effects. Research interest in this peptide centers on its selective interaction with the innate repair receptor (IRR), a heteromeric complex composed of the erythropoietin receptor and the beta-common receptor subunit (CD131). Preclinical investigations have examined ARA-290 in models of neuropathic pain, small-fiber neuropathy, and inflammatory tissue injury.

Research Overview

Because ARA-290 activates the innate repair receptor rather than the classical homodimeric EPO receptor, it is frequently used in laboratory settings to help differentiate tissue-protective and anti-inflammatory signaling pathways from erythropoietic pathways. Studies have explored its downstream effects on cytokine expression, neuronal survival signaling, and microvascular integrity in cell culture and animal models.

Key Research Focus Areas

• Innate Repair Receptor Signaling: Investigation of ARA-290’s selective engagement with the IRR complex and downstream JAK2/STAT signaling, independent of erythropoietic activity.
• Neuropathic and Small-Fiber Models: Examination of ARA-290 in preclinical models relevant to peripheral nerve injury and small-fiber neuropathy research.
• Inflammatory and Cytoprotective Pathways: Analysis of ARA-290’s modulation of inflammatory cytokine expression and cellular stress responses in vitro.
• Microvascular and Tissue Integrity: Study of ARA-290’s effects on endothelial and epithelial barrier function in experimental injury models.
• Comparative Pharmacology: Contrast with native erythropoietin and other EPO-derived peptides to clarify structure-activity relationships at the IRR versus the classical EPO receptor.

Cautionary Statement

ARA-290 is a research chemical and should only be handled by qualified personnel within approved academic or institutional research facilities. This product is not intended for human or animal consumption and poses significant risks if misused. Users must adhere to all applicable laboratory safety protocols, including proper disposal procedures for peptide waste. Always consult relevant institutional review boards and ethics committees prior to initiating research activities involving ARA-290.

For research use only. Not for human or animal consumption.